PTC Therapeutics (NASDAQ:PTCT) Given New $64.00 Price Target at JPMorgan Chase & Co.
PTC Therapeutics (NASDAQ:PTCT – Get Rating) had its price target hoisted by JPMorgan Chase & Co. from $57.00 to $64.00 in a research note published on Monday morning, The Fly reports. A number of other equities analysts have also commented on PTCT. Credit Suisse Group boosted their price target on shares of PTC Therapeutics from […]